Your browser doesn't support javascript.
loading
Germline cancer susceptibility in individuals with melanoma.
Funchain, Pauline; Ni, Ying; Heald, Brandie; Bungo, Brandon; Arbesman, Michelle; Behera, Tapas R; McCormick, Shelley; Song, Jung Min; Kennedy, Lucy Boyce; Nielsen, Sarah M; Esplin, Edward D; Nizialek, Emily; Ko, Jennifer; Diaz-Montero, Claudia M; Gastman, Brian; Stratigos, Alexander J; Artomov, Mykyta; Tsao, Hensin; Arbesman, Joshua.
Afiliação
  • Funchain P; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, Ohio. Electronic address: funchap@stanford.edu.
  • Ni Y; Center for Immunotherapy & Precision Immuno-Oncology, Cleveland Clinic Foundation, Cleveland, Ohio.
  • Heald B; Genomic Medicine Institute, Cleveland Clinic Foundation, Cleveland, Ohio; Invitae Corporation, South San Francisco, California.
  • Bungo B; Medicine Institute, Cleveland Clinic Foundation, Cleveland, Ohio.
  • Arbesman M; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, Ohio.
  • Behera TR; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, Ohio; Center for Immunotherapy & Precision Immuno-Oncology, Cleveland Clinic Foundation, Cleveland, Ohio.
  • McCormick S; Center Cancer Risk Assessment, Massachusetts General Hospital, Cambridge, Massachusetts.
  • Song JM; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, Ohio; Department of Hematology/Oncology, MetroHealth, Cleveland, Ohio.
  • Kennedy LB; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, Ohio.
  • Nielsen SM; Invitae Corporation, South San Francisco, California.
  • Esplin ED; Invitae Corporation, South San Francisco, California.
  • Nizialek E; Department of Medical Oncology, Johns Hopkins University, Baltimore, Maryland.
  • Ko J; The Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, Ohio; Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio.
  • Diaz-Montero CM; Center for Immunotherapy & Precision Immuno-Oncology, Cleveland Clinic Foundation, Cleveland, Ohio.
  • Gastman B; Dermatology and Plastic Surgery Institute, Cleveland Clinic Foundation, Cleveland, Ohio.
  • Stratigos AJ; Department of Dermatology-Venereology, A. Sygros Hospital Medical School, University of Athens, Athens, Greece.
  • Artomov M; Broad Institute, Cambridge, Massachusetts.
  • Tsao H; Department of Dermatology, Massachusetts General Hospital, Cambridge, Massachusetts.
  • Arbesman J; Dermatology and Plastic Surgery Institute, Cleveland Clinic Foundation, Cleveland, Ohio.
J Am Acad Dermatol ; 2024 Mar 20.
Article em En | MEDLINE | ID: mdl-38513832
ABSTRACT

BACKGROUND:

Prior studies have estimated a small number of individuals with melanoma (2%-2.5%) have germline cancer predisposition, yet a recent twin study suggested melanoma has the highest hereditability among cancers.

OBJECTIVE:

To determine the incidence of hereditary melanoma and characterize the spectrum of cancer predisposition genes that may increase the risk of melanoma.

METHODS:

Four hundred individuals with melanoma and personal or family history of cancers underwent germline testing of >80 cancer predisposition genes. Comparative analysis of germline data was performed on 3 additional oncologic and dermatologic data sets.

RESULTS:

Germline pathogenic/likely pathogenic (P/LP) variants were identified in 15.3% (61) individuals with melanoma. Most variants (41, 67%) involved genes considered unrelated to melanoma (BLM, BRIP1, CHEK2, MLH1, MSH2, PMS2, RAD51C). A third (20, 33%) were in genes previously associated with familial melanoma (BAP1, BRCA2, CDKN2A, MITF, TP53). Nearly half (30, 46.9%) of P/LP variants were in homologous repair deficiency genes. Validation cohorts demonstrated P/LP rates of 10.6% from an unselected oncologic cohort, 15.8% from a selected commercial testing cohort, and 14.5% from a highly selected dermatologic study.

LIMITATIONS:

Cohorts with varying degrees of selection, some retrospective.

CONCLUSION:

Germline predisposition in individuals with melanoma is common, with clinically actionable findings diagnosed in 10.6% to 15.8%.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: J Am Acad Dermatol Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: J Am Acad Dermatol Ano de publicação: 2024 Tipo de documento: Article